Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Clinical trial NCT03111732 · COMPLETED
Trial details
- NCT number
- NCT03111732
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-14
- Primary completion
- 2020-07-22
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.